Page 12 - Harvard Bioscience News Today

The Business Research Company’s Laboratory Centrifuge Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

Wall Street analysts expect that Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) will report earnings per share of $0.05 for the current quarter, Zacks reports. Two analysts have provided estimates for Harvard Bioscience’s earnings. Harvard Bioscience also posted earnings of $0.05 per share in the same quarter last year. The business is expected to issue […]

Harvard Bioscience (NASDAQ:HBIO – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and […]

HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Tuesday reported fourth-quarter...

HOLLISTON, Mass. (AP) _ Harvard Bioscience Inc. (HBIO) on Tuesday reported fourth-quarter net income of $961,000, after reporting a loss in the same period a year earlier. On a per-share basis, the Holliston, Massachusetts-based company said it had profit of 2 cents.

Read our preview of key economic and company events in the week ahead, including the ECBs interest rate decision, US CPI for February, and corporate earnings from Greggs, Rivian, and more.

Read our preview of key economic and company events in the week ahead, including the ECBs interest rate decision, US CPI for February, and corporate earnings from Greggs, Rivian, and more.

Analysts expect Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) to post $0.09 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Harvard Bioscience’s earnings. Harvard Bioscience posted earnings per share of $0.08 during the same quarter last year, which indicates a positive year-over-year growth rate of 12.5%. The […]

A liability insurer that abruptly stopped paying defense costs four years into a wrongful death case was in breach of its duty to defend, a Superior Court judge has held. Defendants Biostage and Harvard Bioscience, a pair of biotech companies, were defendants in a lawsuit alleging that a synthetic trachea implant they developed caused a ...

HOLLISTON, Mass., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended...